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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of interventions to enhance adherence to any aspect of treatment in adults with bronchiectasis in terms of adherence
and health outcomes, such as pulmonary exacerbations, health-related quality of life and healthcare costs.
B A C K G R O U N D
Description of the condition
More than 600 million people worldwide suffer from chronic res-
piratory disease (WHO 2007), leading to 4.2 million deaths an-
nually (WHO 2010). Bronchiectasis is an underdiagnosed and
underinvestigated condition; research into new treatments is ur-
gently required to improve the health status of patients with this
condition (Gibson 2013). The global prevalence of bronchiectasis
is currently not known. The most recent prevalence study, which
was conducted in the United States, demonstrated that prevalence
of the condition is increasing at a rate of 8.7% annually, with
an eight-year prevalence of 1106 per 100,000 of the population
(Seitz 2012). Bronchiectasis-associated annual healthcare costs are
estimated at US$630 million (Weycker 2005), and bronchiecta-
sis-associated hospital admissions range between two and six per
100,000 in Europe (Gibson 2013). Given the recognised under-
diagnosis of this condition, it is likely that prevalence and the as-
sociated healthcare burden are even greater than reported.
Description of the intervention
No treatments have been licenced for use in patients with
bronchiectasis. Patients are treated with a complex regimen of
medication and airway clearance techniques that have been ex-
trapolated from other chronic respiratory diseases such as cystic
fibrosis (CF), chronic obstructive pulmonary disease (COPD) and
asthma. Airway clearance techniques such as the Acapella® and
the active cycle of breathing technique are recommended to be
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prescribed for patients with this condition (Pasteur 2010), but ev-
idence of their long-term effectiveness is insufficient (Lee 2013).
The aimof prescribed treatments in bronchiectasis is to reduce pul-
monary exacerbations, improve health-related quality of life and
reduce hospital admissions (Pasteur 2010). However, we recently
reported that adherence was low in bronchiectasis, with as few as
53% of patients categorised as adherent to medication and 41%
categorised as adherent to airway clearance (McCullough 2013).
We have also demonstrated that those who were adherent to in-
haled antibiotics had significantly fewer pulmonary exacerbations
than those who were non-adherent (McCullough 2013). The first
randomised controlled trial to test the effectiveness of colistin (in-
haled antibiotic therapy) for use in bronchiectasis demonstrated
that individuals who were adherent to treatment (i.e. took 80% or
more of prescribedmedication) had a longer time to first exacerba-
tion and better health-related quality of life (Haworth 2013). This
illustrates the importance of adherence to treatment in determin-
ing health outcomes and highlights the need to enhance adher-
ence in this patient population. New therapies are being adapted
and tested in patients with bronchiectasis (Altenburg 2013; Bilton
2013; Haworth 2013; Serisier 2013; Wilson 2013), and it is likely
that the burden of treatment for those with bronchiectasis will
continue to grow. This increasing treatment complexity may af-
fect adherence to new and existing treatments. However, little is
known about the types of adherence interventions that have been
used in bronchiectasis or which, if any, are effective.
How the intervention might work
Adherence is a complex behavioural process; thus, no single mech-
anism is known for adherence to behaviour change. Adherence in-
terventions use educational, psychological and behavioural tech-
niques, in isolation or in combination with each other, to alter
adherence behaviour. However, education alone is insufficient to
alter adherence behaviour (Haynes 2008). Enhanced adherence
may lead to improved health outcomes, including reductions in
pulmonary exacerbations and in healthcare costs with bronchiec-
tasis. Patients may experience improved health-related quality of
life as a consequence of enhanced adherence.
Why it is important to do this review
Low adherence is associated with more frequent pulmonary ex-
acerbations for patients with bronchiectasis (McCullough 2013).
Therefore, enhancing adherence has the potential to lead to im-
proved health outcomes in this patient population. Little is known
about the types of adherence interventions that have been used in
bronchiectasis or which, if any, are effective.We will analyse exist-
ing randomised controlled trials to determine the content of the
interventions that have been tested in this population and their
effectiveness in enhancing adherence and health outcomes.
O B J E C T I V E S
To assess the effects of interventions to enhance adherence to any
aspect of treatment in adults with bronchiectasis in terms of ad-
herence and health outcomes, such as pulmonary exacerbations,
health-related quality of life and healthcare costs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude studies reported as full text, those published as abstract only
and unpublished data. Both parallel and cross-over group designs
will be included.
Types of participants
We will include adults (18 years of age or older) with bronchiecta-
sis diagnosed by high-resolution computed tomography. We will
include both those who are acutely unwell and those who are sta-
ble. We will exclude participants with bronchiectasis caused by
underlying cystic fibrosis. Studies that include only a subset of
relevant participants will be included when data from those par-
ticipants are analysed and reported separately.
Types of interventions
We will include trials comparing any intervention aimed at en-
hancing adherence (including selfmanagement, education, service
developments, reminders and other psychological and behavioural
techniques) versus no intervention, usual care or another adher-
ence intervention. Studies comparing two different treatment in-
terventions (e.g. those comparing one type of medication, airway
clearance technique, inhaler, mask or nebuliser versus another) and
those that merely report adherence to treatment will be excluded.
Types of outcome measures
Reporting in the trial one or more of the outcomes listed here is
not an inclusion criterion for the review. Studies will be included
on the basis of type of study, participants and interventions. We
will extract data collected at the end of the intervention period
(i.e. after the last intervention) and at the end of the study follow-
up (i.e. the end of the study), if different from data obtained at
the end of the intervention period.When appropriate, we will also
extract data collected at interim time points (i.e. data collected
at time points other than end of the intervention and end of the
study).
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Primary outcomes
1. Adherence to at least one aspect of treatment (medication,
airway clearance, medical devices or physical activity) as
measured by direct (e.g. electronic monitoring, directly observed
therapy) or indirect methods (e.g. self report, prescription refill
data).
2. Rate of, duration of or time to first pulmonary exacerbation
of bronchiectasis, defined according to the investigators’
definition.
Secondary outcomes
1. Time to hospitalisation, number of hospital admissions or
hospital days for a pulmonary exacerbation of bronchiectasis.
2. Pulmonary function measures (forced expiratory volume in
one second (FEV1), forced vital capacity (FVC), FEV1/FVC,
forced expiratory flow (FEF)25−75, peak expiratory flow (PEF)).
3. Health-related quality of life measured using a generic or
disease-specific tool (e.g. St George’s Respiratory Questionnaire,
Quality of Life Questionnaire-Bronchiectasis).
4. Exercise capacity as measured by any exercise capacity tool
(e.g. six-minute walk test, incremental shuttle walk test).
5. Healthcare costs including costs of intervention, costs of
devices and overall expenditures.
6. Any adverse events associated with adherence or non-
adherence to treatment.
Adherence to treatment is a primary outcome of this review, as this
is the key outcome that adherence interventions aim to change.
Reducing the frequency, duration of or time to pulmonary exac-
erbations, minimising hospital admissions, improving health-re-
lated quality of life and maintaining pulmonary function are key
clinical outcomes of bronchiectasis treatments (Pasteur 2010) and
thus have been chosen as the clinical outcomes for this review. To
judge whether interventions can be implemented in clinical prac-
tice, it is necessary to know the cost-effectiveness of the interven-
tion. Finally, to ensure patient safety, it is important to be aware
of any adverse events associated with the intervention.
Search methods for identification of studies
Electronic searches
We will identify trials from the Cochrane Airways Group Spe-
cialised Register (CAGR), which is maintained by the Trials
Search Co-ordinator for the Group. The Register contains trial
reports identified through systematic searches of bibliographic
databases including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED
and PsycINFO and by handsearching of respiratory journals and
meeting abstracts (see Appendix 1 for further details). We will
search all records in the CAGR using the search strategy pro-
vided in Appendix 2. We will also conduct a search of ClinicalTri-
als.gov (www.ClinicalTrials.gov) and theWorld Health Organiza-
tion (WHO) trials portal (www.who.int/ictrp/en/). We will search
all databases from the time of their inception to the present, and
we will impose no restriction on language of publication.
Searching other resources
We will check reference lists of all primary studies and review arti-
cles for additional references. We will search relevant manufactur-
ers’ websites for trial information. We will search for errata or re-
tractions from included studies published in full text on PubMed
(www.ncbi.nlm.nih.gov/pubmed) and will report within the re-
view the date this was done.
Data collection and analysis
Selection of studies
Two review authors (AMcC and CR) will independently screen
titles and abstracts for inclusion of all potential studies identified
as a result of the search and will code them as ’retrieve’ (eligi-
ble or potentially eligible/unclear) or ’do not retrieve’. We will re-
trieve the full-text study reports/publications, and two review au-
thors (AMcC and CR) will independently screen the full text and
identify studies for inclusion, and will identify and record reasons
for exclusion of ineligible studies. We will resolve disagreements
through discussion, or, if required, we will consult a third review
author (CH). We will identify and exclude duplicates and will col-
late multiple reports of the same study, so that each study rather
than each report is the unit of interest in the review. We will record
the selection process in sufficient detail to complete a PRISMA
flow diagram and a ’Characteristics of excluded studies’ table.
Data extraction and management
We will document study characteristics and outcome data using a
data collection form that has been piloted on at least one study in
the review. Two review authors (AMcC and CR) will extract the
following study characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals and date of study.
2. Participants: number of participants, mean age, age range,
gender, ethnicity, educational level, severity of condition,
diagnostic criteria, baseline lung function, smoking history,
inclusion criteria and exclusion criteria.
3. Interventions: description of the intervention including
duration of run-in, intervention and follow-up; type of
intervention (including its components (e.g. self management,
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education, service developments, reminders and other
psychological and behavioural components), how and where it
was delivered, by whom and its theoretical rationale) and type of
control group.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (AMcC and CR) will independently extract
outcome data from included studies. We will note in the ’Char-
acteristics of included studies’ table if outcome data were not re-
ported in a usable way. We will resolve disagreements by consen-
sus or by involving a third review author (CH). One review au-
thor (AMcC) will transfer data into the ReviewManager (RevMan
2012) file. We will double-check that data have been entered cor-
rectly by comparing the data presented in the systematic review
versus information provided in the study reports. A second review
author (CR or CH) will spot-check study characteristics against
the trial report to confirm accuracy.
Assessment of risk of bias in included studies
Two review authors (AMcC andCR) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve disagreements by discussion or by involving an-
other review author (CH). We will assess the risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and will provide in the ’Risk of bias’ table a quote from the study
report together with a justification for our judgement. We will
summarise the risk of bias judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes when necessary (e.g. for unblinded out-
come assessment, risk of bias for hospital admissions may be very
different than for patient-reported adherence).When information
on risk of bias relates to unpublished data or correspondence with
a trialist, we will note this in the ’Risk of bias’ table. We will take
into account the risk of bias of the included studies when consid-
ering treatment effects for each outcome.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and will report any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and continuous
data as mean differences or standardised mean differences.We will
enter presented data as a scale with a consistent direction of effect.
We will undertakemeta-analyses only when this is meaningful (i.e.
when treatments, participants and the underlying clinical ques-
tion are similar enough for pooling to make sense). We will narra-
tively describe skewed data reported as medians and interquartile
ranges. When multiple trial arms are reported in a single trial, we
will include only the relevant arms. Whentwo comparisons (e.g.
intervention A vs control and intervention B vs control) are com-
bined in the same meta-analysis, we will halve the control group
to avoid double-counting.
Unit of analysis issues
For dichotomous data, we will report the proportion of partici-
pants contributing to each outcome in comparison with the total
number randomly assigned. For continuous data, the mean dif-
ference based on change from baseline will be preferred over the
mean difference based on absolute. The unit of analysis will be the
person. For cluster-randomised trials, to avoid a unit of analysis
error, sensitivity analysis will occur at the participant level and will
incorporate adjustment using the intra class correlation coefficient
(ICC).
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study is identified as an abstract only).
When this is not possible and the missing data are thought to in-
troduce serious bias, we will explore the impact of including such
studies in the overall assessment of results by performing a sensi-
tivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify moderate (I² = 30% to 60%)
or substantial heterogeneity (I² = 50% to 90%) (Higgins 2011),
we will report this and will explore possible causes by prespecified
subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and
examine a funnel plot to explore possible small-study biases.
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Data synthesis
If a meta-analysis is appropriate, we will use a fixed-effect model.
If heterogeneity cannot be explained by the prespecified subgroup
and sensitivity analyses, we will perform a sensitivity analysis using
the random-effects model. If a meta-analysis is not appropriate,
we will conduct a narrative synthesis of included studies.
Summary of findings table
We will create a ’Summary of findings’ table using the primary
and secondary outcomes stated previously. We will use the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of a body of evidence as it relates to the studies that contribute
data to the meta-analyses for the prespecified outcomes. We will
use methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011) and will use GRADEpro software.
We will justify all decisions to downgrade or upgrade the quality
of studies by using footnotes, and we will make comments to aid
readers’ understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Type of intervention delivered.
2. Healthcare professional who delivered intervention
(physician vs non-physician led, e.g. nurses compared with
physiotherapists, pharmacists and other professionals).
3. Clinical setting (hospital care vs community services).
4. Duration of intervention (one-off intervention compared
with more than one intervention).
5. Disease status (acute vs stable participants).
We will use the following outcomes in subgroup analyses.
1. Adherence to at least one aspect of treatment (medication,
airway clearance, medical devices or physical activity) as
measured by direct (e.g. electronic monitoring, directly observed
therapy) or indirect methods (e.g. self report, prescription refill
data).
2. Rate of, duration of or time to first pulmonary exacerbation
of bronchiectasis, defined according to the investigators’
definition.
We will use the formal test for subgroup interactions in Review
Manager (RevMan 2012). When both acute and stable partici-
pants are included in a study, we will explore them by subgroup
analysis only if the results are reported separately.
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
1. Sensitivity analysis excluding studies with a high risk of bias
based on the ’Risk of bias’ assessment.
2. Studies with less than 80% follow-up.
Reaching conclusions
We will base our conclusions only on findings from the quantita-
tive or narrative synthesis of included studies for this review. We
will avoid making recommendations for practice, and our impli-
cations for research will suggest priorities for future research and
will outline remaining uncertainties.
Results
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
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Database Frequency of search
CENTRAL Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
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4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Medication Adherence
#6 MeSH DESCRIPTOR Patient Acceptance of Health Care Explode All
#7 MeSH DESCRIPTOR Patient Dropouts
#8 complian* or noncomplian* or non-complian*
#9 adhere* or nonadhere* or non-adhere*
#10 persist*
#11 refusal or refuse*
#12 concord*
#13 co-operate*
#14 conform*
#15 accept*
#16 comply*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in which the reference record has been coded for condition, in this case, bronchiectasis]
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